DOI . ORG {
}
Title[redir]:
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer | Investigational New Drugs
Description:
Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
Matching Content Categories {📚}
- Health & Fitness
- Education
- Telecommunications
Content Management System {📝}
What CMS is doi.org built with?
Custom-built
No common CMS systems were detected on Doi.org, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of doi.org audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Doi.org Make Money? {💸}
We find it hard to spot revenue streams.
The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org has a secret sauce for making money, but we can't detect it yet.
Keywords {🔍}
cancer, breast, google, scholar, article, patients, pubmed, cas, metastatic, phase, acid, trial, paclitaxel, retinoic, clin, alltrans, weekly, oncol, privacy, cookies, content, research, treatment, progression, survival, center, months, cells, usa, data, information, publish, search, taxol, recurrent, robert, response, time, results, access, study, winer, res, tamoxifen, kinase, log, journal, drugs, pilot, vesanoid,
Topics {✒️}
asp-glu-val-asp-directed chemotherapy-induced cell death jun n-terminal kinase month download article/chapter tracie saunders & robert wieder 45 mg/m2 po daily cell-specific additive effects study drug supplied jersey medical school trans retinoic acid trans-retinoic acid trans-retinoic acid breast cancer cells differentiation-inducing therapy metastatic breast cancer combination therapy 9-cis retinoic acid phase ii trial chemoresistant breast cancer full article pdf privacy choices/manage cookies related subjects somerset medical center advanced breast cancer steeplechase cancer center cancer center h1216 paclitaxel-induced apoptosis additional information support recurrent breast cancer breast cancer patients anglo-celtic iv previously treated metastatic european economic area hoffman-la roche 4 days starting 2 days bristol-myers squibb primarily african american infusion hypersensitivity reaction withholding dexamethasone premedication subsequent bcl-2 phosphorylation alpha-interferon 2a 1007/s10637-010-9478-3 keywords conditions privacy policy breast cancer article investigational higher-dose paclitaxel article bryan accepting optional cookies kaiser-kupfer mi cancer center
Schema {🗺️}
WebPage:
mainEntity:
headline:A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
description:Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
datePublished:2010-07-02T00:00:00Z
dateModified:2010-07-02T00:00:00Z
pageStart:1482
pageEnd:1487
sameAs:https://doi.org/10.1007/s10637-010-9478-3
keywords:
All trans retinoic acid
Taxol
Metastatic breast cancer
Potentiation
Oncology
Pharmacology/Toxicology
image:
isPartOf:
name:Investigational New Drugs
issn:
1573-0646
0167-6997
volumeNumber:29
type:
Periodical
PublicationVolume
publisher:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Margarette Bryan
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:E. Dianne Pulte
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Kathleen C. Toomey
affiliation:
name:The Steeplechase Cancer Center at Somerset Medical Center
address:
name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
type:PostalAddress
type:Organization
type:Person
name:Lillian Pliner
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Anna C. Pavlick
affiliation:
name:New York University Cancer Institute
address:
name:New York University Cancer Institute, New York, USA
type:PostalAddress
type:Organization
type:Person
name:Tracie Saunders
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Robert Wieder
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:UMDNJ-New Jersey Medical School
address:
name:UMDNJ-New Jersey Medical School, Newark, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
description:Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
datePublished:2010-07-02T00:00:00Z
dateModified:2010-07-02T00:00:00Z
pageStart:1482
pageEnd:1487
sameAs:https://doi.org/10.1007/s10637-010-9478-3
keywords:
All trans retinoic acid
Taxol
Metastatic breast cancer
Potentiation
Oncology
Pharmacology/Toxicology
image:
isPartOf:
name:Investigational New Drugs
issn:
1573-0646
0167-6997
volumeNumber:29
type:
Periodical
PublicationVolume
publisher:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Margarette Bryan
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:E. Dianne Pulte
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Kathleen C. Toomey
affiliation:
name:The Steeplechase Cancer Center at Somerset Medical Center
address:
name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
type:PostalAddress
type:Organization
type:Person
name:Lillian Pliner
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Anna C. Pavlick
affiliation:
name:New York University Cancer Institute
address:
name:New York University Cancer Institute, New York, USA
type:PostalAddress
type:Organization
type:Person
name:Tracie Saunders
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
type:Person
name:Robert Wieder
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:UMDNJ-New Jersey Medical School
address:
name:UMDNJ-New Jersey Medical School, Newark, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Investigational New Drugs
issn:
1573-0646
0167-6997
volumeNumber:29
Organization:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
name:The Steeplechase Cancer Center at Somerset Medical Center
address:
name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
type:PostalAddress
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
name:New York University Cancer Institute
address:
name:New York University Cancer Institute, New York, USA
type:PostalAddress
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
name:UMDNJ-New Jersey Medical School
address:
name:UMDNJ-New Jersey Medical School, Newark, USA
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Margarette Bryan
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:E. Dianne Pulte
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:Kathleen C. Toomey
affiliation:
name:The Steeplechase Cancer Center at Somerset Medical Center
address:
name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
type:PostalAddress
type:Organization
name:Lillian Pliner
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:Anna C. Pavlick
affiliation:
name:New York University Cancer Institute
address:
name:New York University Cancer Institute, New York, USA
type:PostalAddress
type:Organization
name:Tracie Saunders
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:Robert Wieder
affiliation:
name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
address:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
type:PostalAddress
type:Organization
name:UMDNJ-New Jersey Medical School
address:
name:UMDNJ-New Jersey Medical School, Newark, USA
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
name:New York University Cancer Institute, New York, USA
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
name:UMDNJ-New Jersey Medical School, Newark, USA
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(146)
- How much profit does https://link.springer.com/privacystatement make?
- How much profit is https://link.springer.com/article/10.1007/s10637-010-9478-3/#main making per month?
- https://link.springer.com's revenue stream
- How much does https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s10637-010-9478-3 gross monthly?
- Income figures for https://link.springer.com/article/10.1007/s10637-010-9478-3/#eds-c-header-nav
- Revenue of https://link.springer.com/journals/
- Profit of https://www.springernature.com/gp/authors
- What's the monthly money flow for https://link.springernature.com/home/?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/#eds-c-header-popup-search rake in every month?
- How much does https://order.springer.com/public/cart generate monthly?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/ net monthly?
- What's the financial intake of https://link.springer.com/article/10.1007/s10637-010-9478-3/journal/10637?
- How much profit does https://link.springer.com/article/10.1007/s10637-010-9478-3/#citeas make?
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/journal/10637/aims-and-scope produce monthly?
- How profitable is https://submission.nature.com/new-submission/10637/3?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Margarette-Bryan-Aff1 bring in each month?
- What are the earnings of https://link.springer.com/article/10.1007/s10637-010-9478-3/#Aff1?
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-E__Dianne-Pulte-Aff1 generate?
- https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Kathleen_C_-Toomey-Aff2's revenue stream
- Get to know what's the income of https://link.springer.com/article/10.1007/s10637-010-9478-3/#Aff2
- What's the total monthly financial gain of https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Lillian-Pliner-Aff1?
- What's the revenue for https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Anna_C_-Pavlick-Aff3?
- Financial intake of https://link.springer.com/article/10.1007/s10637-010-9478-3/#Aff3
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Tracie-Saunders-Aff1 produce monthly?
- https://link.springer.com/article/10.1007/s10637-010-9478-3/#auth-Robert-Wieder-Aff1-Aff4's financial summary
- Earnings of https://link.springer.com/article/10.1007/s10637-010-9478-3/#Aff4
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/article/10.1007/s10637-010-9478-3/metrics generate monthly?
- What's the income of https://wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10637-010-9478-3?
- What is the earnings of https://link.springer.com/product/springer-plus?
- What's the monthly money flow for https://www.springernature.com/gp/librarians/licensing/agc/journals?
- What's the financial outcome of https://link.springer.com/10.1007/978-1-4939-9585-1_17?fromPaywallRec=true?
- https://link.springer.com/10.1007/s10549-018-05100-z?fromPaywallRec=true's total income per month
- How much does https://link.springer.com/10.1007/s00520-018-4087-3?fromPaywallRec=true make?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/breast-cancer make?
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/cancer-therapeutic-resistance bring in?
- Get to know what's the income of https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/chemotherapy
- Earnings of https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/combination-drug-therapy
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/peripheral-tolerance pull in monthly?
- How much profit is https://link.springer.com/article/10.1007/s10637-010-9478-3/subjects/targeted-therapies making per month?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16368868 make?
- How much income does http://scholar.google.com/scholar_lookup?&title=Extending%20survival%20with%20chemotherapy%20in%20metastatic%20breast%20cancer&journal=Oncologist&doi=10.1634%2Ftheoncologist.10-90003-20&volume=10&issue=Suppl%203&pages=20-29&publication_year=2005&author=O%E2%80%99Shaughnessy%2CJ have?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15957963's earnings
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD2MXltFeksb8%3D produce monthly?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20taxanes%20in%20the%20treatment%20of%20breast%20cancer&journal=Expert%20Opin%20Pharmacother&doi=10.1517%2F14656566.6.7.1073&volume=6&pages=1073-1094&publication_year=2005&author=Nabholtz%2CJM&author=Gligorov%2CJ?
- http://scholar.google.com/scholar_lookup?&title=Taxane%20containing%20regimens%20for%20metastatic%20breast%20cancer&journal=Cochrane%20Database%20Syst%20Rev&volume=3&publication_year=2005&author=Ghersi%2CD&author=Wilcken%2CN&author=Simes%2CJ&author=Donoghue%2CE's total income per month
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18068131 pull in?
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD1cXkvFWlu78%3D generate?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Taxanes%2C%20microtubules%20and%20chemoresistant%20breast%20cancer&journal=Biochim%20Biophys%20Acta&volume=1785&pages=96-132&publication_year=2008&author=McGrogan%2CBT&author=Gilmartin%2CB&author=Carney%2CDN&author=McCann%2CA produce monthly?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15169793?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD2cXpsVWls7g%3D pull in?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Failure%20of%20higher-dose%20paclitaxel%20to%20improve%20outcome%20in%20patients%20with%20metastatic%20breast%20cancer%3A%20cancer%20and%20leukemia%20group%20B%20trial%209342&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2004.08.048&volume=22&pages=2061-2068&publication_year=2004&author=Winer%2CEP&author=Berry%2CDA&author=Woolf%2CS&author=Duggan%2CD&author=Kornblith%2CA&author=Harris%2CLN&author=Michaelson%2CRA&author=Kirshner%2CJA&author=Fleming%2CGF&author=Perry%2CMC&author=Graham%2CML&author=Sharp%2CSA&author=Keresztes%2CR&author=Henderson%2CIC&author=Hudis%2CC&author=Muss%2CH&author=Norton%2CL?
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18375893?
- https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD1cXltlWhsr0%3D's revenue stream
- How much does http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20trial%20of%20weekly%20compared%20with%20every-3-weeks%20paclitaxel%20for%20metastatic%20breast%20cancer%2C%20with%20trastuzumab%20for%20all%20HER-2%20overexpressors%20and%20random%20assignment%20to%20trastuzumab%20or%20not%20in%20HER-2%20nonoverexpressors%3A%20final%20results%20of%20Cancer%20and%20Leukemia%20Group%20B%20protocol%209840&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2007.11.6699&volume=26&pages=1642-1649&publication_year=2008&author=Seidman%2CAD&author=Berry%2CD&author=Cirrincione%2CC&author=Harris%2CL&author=Muss%2CH&author=Marcom%2CPK&author=Gipson%2CG&author=Burstein%2CH&author=Lake%2CD&author=Shapiro%2CCL&author=Ungaro%2CP&author=Norton%2CL&author=Winer%2CE&author=Hudis%2CC pull in?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10766196 pull in?
- What's the monthly income of https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3cXisVymsrY%3D?
- How much does http://scholar.google.com/scholar_lookup?&title=1%2C%2025%28OH%292%20vitamin%20D3%20and%20all-trans%20retinoic%20acid%20sensitize%20breast%20cancer%20cells%20to%20chemotherapy-induced%20cell%20death&journal=Cancer%20Res&volume=60&pages=2040-2048&publication_year=2000&author=Wang%2CQ&author=Yang%2CW&author=Uytingco%2CMS&author=Christakos%2CS&author=Wieder%2CR make?
- How much cash flow does https://link.springer.com/doi/10.1007/s002800050666 have monthly?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9225952's earnings
- What's the income generated by https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DyaK2sXksVOksrw%3D each month?
- http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20and%20clinical%20impact%20of%20all-trans%20retinoic%20acid%20in%20metastatic%20breast%20cancer%3A%20a%20phase%20II%20trial&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs002800050666&volume=40&pages=335-341&publication_year=1997&author=Sutton%2CLM&author=Warmuth%2CMA&author=Petros%2CWP&author=Winer%2CEP's total income per month
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9816171
- How much profit does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DyaK28Xhs1SktLw%3D make?
- http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%209-cis%20retinoic%20acid%20in%20adults%20with%20solid%20tumors&journal=Clin%20Cancer%20Res&volume=2&pages=287-293&publication_year=1996&author=Kurie%2CJM&author=Lee%2CJS&author=Griffin%2CT&author=Lippman%2CSM&author=Drum%2CP&author=Thomas%2CMP&author=Weber%2CC&author=Bader%2CM&author=Massimini%2CG&author=Hong%2CWK income
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12637463 produce monthly?
- What's the financial gain of https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD2cXpsVGqsLg%3D?
- How much money does http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20II%20study%20of%20oral%20bexarotene%20for%20patients%20with%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2003.05.068&volume=21&pages=999-1006&publication_year=2003&author=Esteva%2CFJ&author=Glaspy%2CJ&author=Baidas%2CS&author=Laufman%2CL&author=Hutchins%2CL&author=Dickler%2CM&author=Tripathy%2CD&author=Cohen%2CR&author=DeMichele%2CA&author=Yocum%2CRC&author=Osborne%2CCK&author=Hayes%2CDF&author=Hortobagyi%2CGN&author=Winer%2CE&author=Demetri%2CGD make?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10637240?
- How much profit does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3cXps1Oruw%3D%3D make?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Pilot%20trial%20of%20the%20safety%2C%20tolerability%2C%20and%20retinoid%20levels%20of%20N-%284-hydroxyphenyl%29%20retinamide%20in%20combination%20with%20tamoxifen%20in%20patients%20at%20high%20risk%20for%20developing%20invasive%20breast%20cancer&journal=J%20Clin%20Oncol&volume=18&pages=275-283&publication_year=2000&author=Conley%2CB&author=O%E2%80%99Shaughnessy%2CJ&author=Prindiville%2CS&author=Lawrence%2CJ&author=Chow%2CC&author=Jones%2CE&author=Merino%2CMJ&author=Kaiser-Kupfer%2CMI&author=Caruso%2CRC&author=Podgor%2CM&author=Goldspiel%2CB&author=Venzon%2CD&author=Danforth%2CD&author=Wu%2CS&author=Noone%2CM&author=Goldstein%2CJ&author=Cowan%2CKH&author=Zujewski%2CJ
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11352969 make?
- How much profit does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3MXkt1Olsr4%3D make?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20clinical%20trial%20of%20alitretinoin%20and%20tamoxifen%20in%20breast%20cancer%20patients%3A%20toxicity%2C%20pharmacokinetic%2C%20and%20biomarker%20evaluations&journal=J%20Clin%20Oncol&volume=19&pages=2754-2763&publication_year=2001&author=Lawrence%2CJA&author=Adamson%2CPC&author=Caruso%2CR&author=Chow%2CC&author=Kleiner%2CD&author=Murphy%2CRF&author=Venzon%2CDJ&author=Shovlin%2CM&author=Noone%2CM&author=Merino%2CM&author=Cowan%2CKH&author=Kaiser%2CM&author=O%E2%80%99Shaughnessy%2CJ&author=Zujewski%2CJ
- How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9533531 have?
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DyaK1cXit1aqurY%3D generate?
- What are the earnings of http://scholar.google.com/scholar_lookup?&title=Phase%20I%2FII%20trial%20of%20all-trans%20retinoic%20acid%20and%20tamoxifen%20in%20patients%20with%20advanced%20breast%20cancer&journal=Clin%20Cancer%20Res&volume=4&pages=635-642&publication_year=1998&author=Budd%2CGT&author=Adamson%2CPC&author=Gupta%2CM&author=Homayoun%2CP&author=Sandstrom%2CSK&author=Murphy%2CRF&author=McLain%2CD&author=Tuason%2CL&author=Peereboom%2CD&author=Bukowski%2CRM&author=Ganapathi%2CR?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11709565
- Explore the financials of https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD38XhslWqtA%3D%3D
- What's http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20II%20trial%20of%20weekly%20paclitaxel%20in%20women%20with%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&volume=19&pages=4216-4223&publication_year=2001&author=Perez%2CEA&author=Vogel%2CCL&author=Irwin%2CDH&author=Kirshner%2CJJ&author=Patel%2CR's gross income?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Anglo-Celtic%20IV%3A%20first%20results%20of%20a%20UK%20National%20Cancer%20Research%20Network%20randomized%20phase%20III%20pharmacogenetic%20trial%20of%20weekly%20compared%20to%203%20weekly%20paclitaxel%20in%20patients%20with%20locally%20advanced%20or%20metastatic%20breast%20cancer%20%28ABC%29&journal=J%20Clin%20Onc%202007%20ASCO%20Annual%20Meeting%20Proceedings&volume=25&publication_year=2007&author=Verrill%2CMW&author=Lee%2CJ&author=Cameron%2CDA&author=Agrawal%2CR&author=Coleman%2CRE&author=McAdam%2CK&author=Wardley%2CA&author=Bowman%2CA&author=Ferrigan%2CL&author=Yellowlees%2CA
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16454751
- https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD28XitlCqtw%3D%3D's financial summary
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Differentiation-inducing%20therapy%20for%20solid%20tumors&journal=Curr%20Pharm%20Des&doi=10.2174%2F138161206775201947&volume=12&pages=379-385&publication_year=2006&author=Kawamata%2CH&author=Tachibana%2CM&author=Fujimori%2CT&author=Imai%2CY
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11160861 earning monthly?
- Find out how much https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3MXnsl2iug%3D%3D earns monthly
- How much money does http://scholar.google.com/scholar_lookup?&title=Involvement%20of%20Asp-Glu-Val-Asp-directed%2C%20caspase-mediated%20mitogen-activated%20protein%20kinase%20kinase%201%20Cleavage%2C%20c-Jun%20N-terminal%20kinase%20activation%2C%20and%20subsequent%20Bcl-2%20phosphorylation%20for%20paclitaxel-induced%20apoptosis%20in%20HL-60%20cells&journal=Mol%20Pharmacol&volume=59&pages=254-262&publication_year=2001&author=Shiah%2CSG&author=Chuang%2CSE&author=Kuo%2CML make?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14724571
- Monthly income for https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD2cXjtFKhtQ%3D%3D
- http://scholar.google.com/scholar_lookup?&title=All-trans%20retinoic%20acid%20potentiates%20Taxotere-induced%20cell%20death%20mediated%20by%20jun%20N-terminal%20kinase%20in%20breast%20cancer%20cells&journal=Oncogene&doi=10.1038%2Fsj.onc.1207040&volume=23&pages=426-433&publication_year=2004&author=Wang%2CQ&author=Wieder%2CR's financial summary
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11519864 income
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3MXmslSns74%3D net monthly?
- What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=1%2C%2025-dihydroxyvitamin%20D3%20and%20retinoic%20acid%20analogues%20induce%20differentiation%20in%20breast%20cancer%20cells%20with%20function-%20and%20cell-specific%20additive%20effects&journal=Breast%20Cancer%20Res%20Treat&doi=10.1023%2FA%3A1010643323268&volume=67&pages=157-168&publication_year=2001&author=Wang%2CQ&author=Lee%2CD&author=Sysounthone%2CV&author=Chandraratna%2CRAS&author=Christakos%2CS&author=Korah%2CR&author=Wieder%2CR?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11029503 generate monthly?
- https://link.springer.com/article/10.1007/s10637-010-9478-3/articles/cas-redirect/1:CAS:528:DC%2BD3cXotVGksLw%3D's financial summary
- How much does http://scholar.google.com/scholar_lookup?&title=Biological%20activity%20of%20all-trans-retinoic%20acid%20with%20and%20without%20tamoxifen%20and%20alpha-interferon%202a%20in%20breast%20cancer%20patients&journal=Int%20J%20Oncol&volume=17&pages=991-1000&publication_year=2000&author=Toma%2CS&author=Raffo%2CP&author=Nicolo%2CG&author=Canavese%2CG&author=Margallo%2CE&author=Vecchio%2CC&author=Dastoli%2CG&author=Iacona%2CI&author=Regazzi-Bonora%2CM gross monthly?
- Financial intake of https://citation-needed.springer.com/v2/references/10.1007/s10637-010-9478-3?format=refman&flavour=references
- What are the total earnings of https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Margarette%20Bryan?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Margarette%20Bryan
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Margarette%20Bryan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
- What's the financial gain of https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=E.%20Dianne%20Pulte?
- What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E.%20Dianne%20Pulte?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E.%20Dianne%20Pulte%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Kathleen%20C.%20Toomey pull in monthly?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kathleen%20C.%20Toomey bring in?
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kathleen%20C.%20Toomey%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much revenue does https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Lillian%20Pliner bring in?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lillian%20Pliner
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lillian%20Pliner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- Revenue of https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Anna%20C.%20Pavlick
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anna%20C.%20Pavlick make?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anna%20C.%20Pavlick%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Tracie%20Saunders generate monthly?
- Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tracie%20Saunders
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tracie%20Saunders%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
- What is the earnings of https://link.springer.com/article/10.1007/s10637-010-9478-3/search?sortBy=newestFirst&dc.creator=Robert%20Wieder?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20Wieder bring in?
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20Wieder%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Get to know https://link.springer.com/article/10.1007/s10637-010-9478-3/mailto:[email protected]'s earnings
- How much does https://s100.copyright.com/AppDispatchServlet?title=A%20pilot%20phase%20II%20trial%20of%20all-trans%20retinoic%20acid%20%28Vesanoid%29%20and%20paclitaxel%20%28Taxol%29%20in%20patients%20with%20recurrent%20or%20metastatic%20breast%20cancer&author=Margarette%20Bryan%20et%20al&contentID=10.1007%2Fs10637-010-9478-3©right=Springer%20Science%2BBusiness%20Media%2C%20LLC&publication=0167-6997&publicationDate=2010-07-02&publisherName=SpringerNature&orderBeanReset=true earn?
- How much does https://citation-needed.springer.com/v2/references/10.1007/s10637-010-9478-3?format=refman&flavour=citation generate monthly?
- How much does https://link.springer.com/article/10.1007/s10637-010-9478-3/search?query=All%20trans%20retinoic%20acid&facet-discipline="Medicine%20%26%20Public%20Health" earn?
- Explore the financials of https://link.springer.com/article/10.1007/s10637-010-9478-3/search?query=Taxol&facet-discipline="Medicine%20%26%20Public%20Health"
- https://link.springer.com/article/10.1007/s10637-010-9478-3/search?query=Metastatic%20breast%20cancer&facet-discipline="Medicine%20%26%20Public%20Health"'s total income per month
- What's the revenue for https://link.springer.com/article/10.1007/s10637-010-9478-3/search?query=Potentiation&facet-discipline="Medicine%20%26%20Public%20Health"?
- What are the earnings of https://link.springer.com/journals/a/1?
- Check the income stats for https://link.springer.com/books/a/1
- How profitable is https://link.springer.com/journals?
- What is the monthly revenue of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
- Discover the revenue of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
- How much does https://www.springernature.com/gp/products pull in?
- What's the financial outcome of https://www.springernature.com/gp/librarians?
- What's https://www.springernature.com/gp/societies's gross income?
- How much money does https://www.springernature.com/gp/partners generate?
- How much does https://www.springer.com/ earn?
- How much does https://www.nature.com/ rake in every month?
- What's the total monthly financial gain of https://www.biomedcentral.com/?
- What's the income generated by https://www.palgrave.com/ each month?
- https://www.apress.com/'s financial summary
- How much does https://link.springer.com/brands/discover pull in?
- See how much https://www.springernature.com/gp/legal/ccpa makes per month
- How profitable is https://www.springernature.com/gp/info/accessibility?
- How profitable is https://link.springer.com/termsandconditions?
- What's the monthly money flow for https://support.springernature.com/en/support/home?
- What's the financial intake of https://link.springer.com/legal-notice?
- How much money does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations make?
- What's the profit of https://www.springernature.com/?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
Emails and Hosting {✉️}
Mail Servers:
- mx.zoho.eu
- mx2.zoho.eu
- mx3.zoho.eu
Name Servers:
- josh.ns.cloudflare.com
- zita.ns.cloudflare.com
CDN Services {📦}
- Crossref